Clinical trials: Immunosuppression
Kidney Transplantation
Everolimus in de Novo Kidney Transplant Recipients
The purpose of this study was to evaluate whether delayed (i.e. 28 ± 4 days post-transplant) administration of everolimus after transplantation reduces the risk of wound healing complications in comparison with immediate…
- Trial name
- NEVERWOUND (NCT01410448)
- Testing
- Everolimus, Mycophenolate sodium, Cyclosporine
- Where
- 22 sites in Italy
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
Myelodysplastic Syndromes
A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome
This study will evaluate the safety and effectiveness of a genetically engineered antibody, alemtuzumab (Campath[R]) on patients with myelodysplastic syndrome.
- Trial name
- NCT00217594
- Testing
- Alemtuzumab (Campath)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Vasculitis
Hematopoietic Stem Cell Support in Vasculitis
The systemic vasculitis is a wide-ranging group of diseases that are characterized by the presence of blood vessel inflammation (1).
- Trial name
- NCT00278512
- Testing
- Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant, Cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Northwestern University
Kidney Transplantation
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection.
- Trial name
- NCT00263328
- Testing
- Tacrolimus, CP-690,550
- Where
- 27 sites in United States
- Volunteers
- 46 people
- Sponsor
- Pfizer
Lymphoma, Multiple Myeloma
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.
- Conditions
- Lymphoma, Multiple Myeloma, Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00809276
- Testing
- Busulfan, Fludarabine, Cytoxan
- Where
- 3 sites in United States
- Volunteers
- 92 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
Budesonide for Liver Transplant Immune Suppression
This is a pilot study that investigates the efficacy and safety of budesonide as an immune suppressing agent for liver transplant recipients in the early post-transplant period.
- Trial name
- NCT03304626
- Testing
- Budesonide 3Mg Capsule, Standard of Care Prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Primary Renal Allograft Candidate, Kidney Transplantation
Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen
The primary objective is to evaluate a NULOJIX® (belatacept) based regimens as a means of improving long-term graft function without increasing the risks of immunologic graft injury by avoiding both calcineurin inhibitors (CNIs)…
- Trial name
- NCT01856257
- Testing
- Anti-thymocyte Globulin (Rabbit), belatacept, methylprednisolone
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
This phase II trial studies how well sirolimus, cyclosporine and mycophenolate mofetil works in preventing graft-vs-host disease (GVHD) in patients with blood cancer undergoing donor peripheral blood stem cell (PBSC) transplant.
- Conditions
- Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma, Adult Myelodysplastic Syndrome
- Trial name
- NCT01251575
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 5 sites in United States, Denmark
- Volunteers
- 77 people
- Sponsor
- Fred Hutchinson Cancer Center
Renal Transplantation
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
The purpose of this trial is to learn if Belatacept is effective and safe as a first line of immunosuppression treatment in patients undergoing a renal transplant where the donor kidney is obtained in patients with extended…
- Trial name
- BENEFIT-EXT (NCT00114777)
- Testing
- Cyclosporin A, Belatacept Less Intensive Regimen (LI), Belatacept More Intensive Regimen (MI)
- Where
- 79 sites in United States, Argentina and 17 more
- Volunteers
- 595 people
- Sponsor
- Bristol-Myers Squibb
Lung Transplant Recipient, SARS-CoV-2
High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients
Lung transplant recipients have poor outcomes after COVID-19 infection with mortality. Due to the immunosuppression, they have had poor responses to SARS-CoV-2 vaccine and remain at high risk of poor outcomes.
- Conditions
- Lung Transplant Recipient, SARS-CoV-2, Immunosuppression
- Trial name
- NCT05280158
- Testing
- mRNA-1273 (Moderna COVID-19 vaccine)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of California, Los Angeles
Kidney Transplantation
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
This study compared the incidence of a two-part composite endpoint consisting of de novo donor specific antibody (DSA) formation or a designation of immune activation (IA) on peripheral blood molecular profiling in participants…
- Trial name
- ASTOUND (NCT02723591)
- Testing
- Tacrolimus, Tacrolimus immediate release
- Where
- 30 sites in United States
- Volunteers
- 599 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Diabetes Mellitus, Type 1
Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression
The primary purpose of this study is to demonstrate the safety of allogeneic islet transplantation in type 1 diabetic patients performed at the University of Illinois at Chicago (UIC).
- Trial name
- NCT00566813
- Testing
- Islet Cell Transplant, Islet Cell Transplant plus
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Illinois Chicago
Kidney Failure
Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function
Tacrolimus is the standard immunosuppressive drug used to prevent organ rejection post liver transplant. One side effect of Tacrolimus is nephrotoxicity. Everolimus does not have the nephrotoxicity side effects of Tacrolimus.
- Trial name
- NCT04258423
- Testing
- Tacrolimus, Everolimus
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Indiana University
Melanoma, Neoplasm Metastasis
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
This experiment will test the safety and effectiveness of a treatment for melanoma in which certain lymphocytes (a type of white blood cell) are taken from the patient, grown in the laboratory, and returned after the patient's…
- Trial name
- NCT00001832
- Testing
- gp100:209-217 (210M), Montanide ISA-51, IL-2
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Kidney Transplant Rejection, Immunosuppression
Immune Monitoring to Facilitate Belatacept Monotherapy
To determine the utility of novel blood-based immune monitoring tools (Allosure and Trugraf) to facilitate belatacept monotherapy.
- Trial name
- NCT04177095
- Testing
- Allosure, Immunosuppression reduction, Trugraf
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Liver Transplant, Kidney Transplant
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
Clinical trial applying Phenotypic Precision Medicine (PPM) to tacrolimus dosing in liver and/or kidney transplant recipients to show improvement in maintaining drug trough levels within the target range.
- Trial name
- PPM - Pro (NCT03527238)
- Testing
- PPM-based Computation Assisted Drug Dosing, Tacrolimus
- Where
- 3 sites in United States, Singapore
- Volunteers
- 62 people
- Sponsor
- University of Florida
Diabetes Mellitus, Type 1
New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial
The objective of this study is to identify immune intervention strategies that will preserve residual beta cell function at the onset of type 1 diabetes.
- Trial name
- TN02 (NCT00100178)
- Testing
- Mycophenolate mofeteil (MMF), Daclizumab (DZB)
- Where
- 11 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Graft Vs Host Disease, GVHD
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
The purpose of this study is to examine a new approach to preventing a serious problem after transplant called graft vs. host disease (abbreviated as GVHD).
- Trial name
- NCT02891603
- Testing
- Pacritinib, Sirolimus, Tacrolimus
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Kidney Failure, Renal Failure
Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
The purpose of this study is to demonstrate the pharmacokinetics (PK, measuring the amount of medication in blood samples) and safety of a new medicine, LCP-Tacro™ tablets, and Prograf® capsules, a drug commonly taken by…
- Trial name
- NCT00765661
- Testing
- Tacrolimus (Tacro™), Prograf
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Veloxis Pharmaceuticals
Hepatitis C, Hepatitis C, Chronic
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
In order to prevent organ rejection, patients receiving liver transplants currently require life-long treatment with immune system-suppressing medications to prevent the rejection of the transplanted liver.
- Conditions
- Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
- Trial name
- A-WISH (NCT00135694)
- Testing
- calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids
- Where
- 8 sites in United States
- Volunteers
- 275 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)